Methyltransferase mutant with improved enzyme activity and application thereof
By performing specific amino acid mutations and site-directed mutations in methyltransferases, the activity of the enzyme is improved, the problem of insufficient catalytic efficiency of methyltransferases is solved, the ability of vanillin is significantly improved, and the efficient vanillin is achieved accumulation.
Patent Information
- Application Number
- CN202411225351.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-22
AI Technical Summary
The catalytic efficiency of methyltransferase in the glucose to vanillin biosynthesis pathway is insufficient, resulting in a low conversion rate of the precursor protocatechic acid to vanillin, affecting the accumulation of vanillin.
Through genetic engineering and enzyme engineering, methyltransferase mutants with increased enzyme activity were constructed, specifically by performing amino acid mutations at positions 98 and/or 43, such as mutation of tryptophan into alanine or lysine and design site-directed mutation mutant primers to construct plasmid vector encoding mutants, transform them into host cells, select positive clones for fermentation and culture, and improve the activity of the enzyme.
Compared with wild-type methyltransferase, the vanillin production of recombinant strains expressing mutants increased by 12.8% to 26.4% at shake flask level, and the vanillin production of mutant W98K/M43Y reached 683.1 mg/ for 60 hours of fermentation. L, reached the highest level of de novo synthesis of vanillin.
Smart Images

Figure CN118995681A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a methyltransferase mutant with improved enzyme activity and application thereof, belonging to the technical field of genetic engineering and enzyme engineering. Background Art
[0002] Vanillin, chemically known as 4-hydroxy-3-methoxybenzaldehyde, is one of the most widely used spices in the world. It has antioxidant, antibacterial and anti-inflammatory effects, and is therefore widely used in food, cosmetics and pharmaceutical fields, and is also partially used in the pesticide industry. At present, the biosynthetic pathway from glucose to vanillin via the dehydroshikimic acid pathway is relatively short and involves fewer heterologous enzymes. Protocatechuic acid is the main precursor of vanillin synthesized via the dehydroshikimic acid pathway. In Escherichia coli, the pathway from dehydroshikimic acid to vanillin requires only three heterologous enzymes to achieve the construction of the metabolic pathway, including dehydroshikimic acid dehydratase that converts dehydroshikimic acid into protocatechuic acid, methyltransferase that converts protocatechuic acid into vanillic acid, and carboxylic acid reductase that converts vanillic acid into vanillin. Currently, methyltransferase is the main limiting factor in the biosynthesis of vanillin via the dehydroshikimic acid pathway. The insufficient catalytic efficiency of methyltransferase seriously affects the conversion of the precursor protocatechuic acid to vanillic acid, which in turn affects the accumulation of vanillin. Therefore, it is crucial to increase the activity of methyltransferase. Summary of the invention
[0003] The inventor team obtained an engineered Escherichia coli K12R that can synthesize vanillin from glucose through screening and construction. The dehydrogenated shikimate dehydratase DSD from Podospora pauciseta, the methyltransferase LiOMT from Leptospira interrogans, and the carboxylic acid reductase NiCAR from Nocardia iowensis were expressed in it, which can produce a large amount of protocatechuic acid accumulation during the fermentation process, and only trace vanillin can be detected. However, when LiOMT and NiCAR were expressed separately in the strain (K12R), their direct precursors protocatechuic acid and vanillic acid were added respectively for whole-cell catalytic reaction, it was observed that the conversion rate of protocatechuic acid was insufficient while the conversion rate of vanillic acid was normal. Therefore, it is inferred that LiOMT is the main rate-limiting step, and increasing the activity of LiOMT enzyme can increase the accumulation of vanillin.
[0004] In order to improve the catalytic rate of methyltransferase, the present invention uses genetic engineering and enzyme engineering to prepare a methyltransferase with improved enzyme activity, which provides a high-efficiency enzyme element for synthesizing vanillin via the dehydroshikimic acid pathway.
[0005] The present invention provides a methyltransferase mutant with improved enzyme activity, which has mutations (a) and / or (b) relative to a parent derived from Leptospira interrogans:
[0006] (a) the tryptophan at position 98 is mutated to alanine, or leucine, or isoleucine, or methionine, or serine, or lysine;
[0007] (b) Methionine at position 43 was mutated to cysteine or tyrosine.
[0008] In one embodiment, the amino acid sequence of the parent methyltransferase LiOMT is shown in SEQ ID NO.1.
[0009] In one embodiment, the mutant is a mutant in which the tryptophan (Trp) at position 98 is mutated to alanine (Ala). The mutant is named W98A and has an amino acid sequence shown in SEQ ID NO.3.
[0010] In one embodiment, the mutant is a mutant in which the tryptophan (Trp) at position 98 is mutated to lysine (Lys). The mutant is named W98K and has an amino acid sequence shown in SEQ ID NO.4.
[0011] In one embodiment, the mutant is a mutant in which the tryptophan (Trp) at position 98 is mutated to lysine (Lys), and the methionine (Met) at position 43 is mutated to tyrosine (Tyr). The mutant is named W98K / M43Y and has the amino acid sequence shown in SEQ ID NO.5.
[0012] The present invention also provides a gene encoding the mutant.
[0013] In one embodiment, the gene has a nucleotide sequence shown in any one of SEQ ID NOs. 6 to 8.
[0014] The invention also provides an expression vector carrying the gene.
[0015] In one embodiment, the vector includes but is not limited to pCDM4 plasmid, and its nucleotide sequence is shown in Add gene Plasmid: #49796.
[0016] In one embodiment, P trc The promoter regulates the expression of the gene; trc The nucleotide sequence of the promoter is shown in SEQ ID NO.10.
[0017] In one embodiment, the expression vector further contains a carboxylic acid reductase gene NiCAR; the gene NiCAR has a nucleotide sequence shown in SEQ ID NO.9.
[0018] In one embodiment, there is a RBS sequence between the gene NiCAR and the mutant gene.
[0019] In one embodiment, the RBS sequence includes but is not limited to the sequence shown in SEQ ID NO.11.
[0020] The present invention also provides a recombinant microbial cell expressing the mutant or containing the gene.
[0021] In one embodiment, the host cell is a bacterial cell.
[0022] In one embodiment, the bacteria are Gram-negative bacteria.
[0023] In one embodiment, the microorganism includes but is not limited to Escherichia coli.
[0024] In one embodiment, the E. coli has a metabolic pathway for synthesizing vanillin using glucose.
[0025] The present invention also provides a recombinant Escherichia coli with improved vanillin synthesis ability, wherein the recombinant Escherichia coli expresses the methyltransferase mutant.
[0026] In one embodiment, the Escherichia coli is a recombinant Escherichia coli K12R, which has been disclosed in the paper "Optimization of vanillin biosynthesis in Escherichia coli K12MG1655 through metabolic engineering" and in a patent application with publication number CN116751730A.
[0027] In one embodiment, the recombinant Escherichia coli uses plasmid pCDM4 as an expression vector to express the mutant.
[0028] The present invention also provides a method for preparing a methyltransferase mutant, comprising the following steps:
[0029] (1) According to the amino acid sequence and crystal structure of the methyltransferase, an enzyme::cofactor::protocatechuic acid::Mg based on the methyltransferase is designed and constructed 2+ Molecular docking model of quaternary complex;
[0030] (2) Based on the molecular docking model of methyltransferase constructed in (1), the cofactor and protocatechuic acid were docked with the enzyme binding site. Amino acid residues were selected within the range as saturation test sites for the spherical combination active site, and all of them were mutated to alanine;
[0031] (3) Designing site-directed mutagenesis primers based on the mutation site determined in (2), and performing site-directed mutagenesis using a vector carrying the methyltransferase gene as a template; and constructing a plasmid vector containing a gene encoding the mutant;
[0032] (4) transforming the mutant plasmid into host cells;
[0033] (5) Select positive clones for fermentation culture.
[0034] In one embodiment, pCDM4 plasmid is used as the expression vector.
[0035] In one embodiment, the PT7 promoter of the expression vector pCDM4 is replaced by P trc Promoter.
[0036] In one embodiment, the expression vector also carries a carboxylic acid reductase gene NiCAR; the gene NiCAR has a nucleotide sequence shown in SEQ ID NO.9.
[0037] The present invention also provides a method for preparing vanillin, which comprises culturing the recombinant Escherichia coli in a medium containing glucose and collecting the vanillin in the fermentation liquid.
[0038] In one embodiment, the method is to culture the recombinant Escherichia coli in a seed culture medium for a period of time as a seed liquid, and then transfer the seed liquid to a fermentation medium for fermentation.
[0039] In one embodiment, the seed culture medium includes but is not limited to LB medium.
[0040] In one embodiment, an inducer is further added during the culture process; the inducer includes but is not limited to IPTG.
[0041] In one embodiment, the culture is first cultured at 37°C for a period of time, then IPTG is added for induction, and the culture is continued at 30°C.
[0042] In one embodiment, the culture is first cultured at 37°C and 220 rpm for 3.5 to 4 h until the OD 600 =0.8~1.0, add 0.5mM IPTG to start induction, and culture at 30℃, 220rpm for 24h.
[0043] In one embodiment, feeding is also performed during the culturing process.
[0044] In one embodiment, the feed is glucose supplementation to make the glucose concentration in the fermentation broth less than 10 g / L.
[0045] In one embodiment, the culture is first cultured at 37°C until the dissolved oxygen rebounds, then cooled to 30°C, induced by adding IPTG at a final concentration of 0.5 mM and starting feeding.
[0046] In one embodiment, the pH of the culture system is controlled to be 6.45-6.55.
[0047] The present invention also provides the use of the mutant, the recombinant Escherichia coli, or the method in preparing vanillin or a product containing vanillin.
[0048] Beneficial effects:
[0049] (1) The present invention targets methyltransferase LiOMT, transforms the amino acid sequence of methyltransferase LiOMT by site-directed mutagenesis biotechnology, and obtains a methyltransferase mutant with improved enzyme activity. Compared with the wild-type methyltransferase LiOMT, the recombinant bacteria expressing the mutant have a stronger ability to synthesize vanillin, wherein the vanillin production of the strain expressing mutant W98A at the shake flask level is about 12.8% higher than that of the wild-type in synthesizing vanillin in the dehydroshikimic acid pathway, the vanillin production of the strain expressing mutant W98K at the shake flask level can be increased by 23.3% compared with the wild-type strain, and the vanillin production of the strain expressing mutant W98K / M43Y at the shake flask level can be increased by 26.4% compared with the wild-type strain.
[0050] (2) The present invention also provides a method for producing vanillin by fermentation in a fermenter using a recombinant strain carrying the methyltransferase LiOMT mutant W98K / M43Y, which can achieve a vanillin yield of 683.1 mg / L after 60 hours of fermentation. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 This is the phylogenetic tree of the relationship between 12 reference samples and the methyltransferase LiOMT.
[0052] Figure 2 The RMSD values of the 12 reference samples were aligned with the structure of methyltransferase LiOMT.
[0053] Figure 3 Molecular docking model for methyltransferase LiOMT enzyme::cofactor SAM.
[0054] Figure 4Molecular docking model of methyltransferase LiOMT enzyme::cofactor SAM::protocatechuic acid.
[0055] Figure 5 Methyltransferase LiOMT enzyme:: cofactor SAM:: protocatechuic acid:: Mg 2+ Molecular docking model.
[0056] Figure 6 This is a diagram for the construction of the methyltransferase LiOMT expression vector (taking pCDM4-W98A as an example) modified by site-directed mutagenesis.
[0057] Figure 7 This is a graph showing the test results of 32 mutants producing vanillin by fermentation.
[0058] Figure 8 This is the test result of fermentation production of vanillin after saturation mutation of amino acid at position 98.
[0059] Figure 9 This is the test result of fermentation production of vanillin after saturation mutation of amino acid at position 43.
[0060] Figure 10 This is the test result of the strain expressing LiMOT mutant W98K / M43Y in a 5L fermenter to expand the culture and synthesize vanillin. DETAILED DESCRIPTION
[0061] 1. Technical terms
[0062] The terms "comprising", "including", "having", and "containing" used in the present invention mean "including but not limited to", "including but not limited to", "having but not limited to", and "containing but not limited to", and can be used interchangeably with corresponding phrases. Unless the context clearly indicates otherwise, the term "or" used in this article is used in this article to mean the term "and / or" and can be used interchangeably with it. Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. Although methods and materials similar or equivalent to the methods and materials described herein can be used in the practice or testing of the present invention, the examples of suitable methods and materials described below are illustrative only and do not limit the present invention in any way.
[0063] The term "expression" as used herein refers to any step involved in the production of an enzyme, protein or polypeptide, including but not limited to transcription, post-transcriptional modification, translation, post-translational modification and secretion.
[0064] The term "vector" as used herein refers to a DNA or RNA molecule containing a gene expression unit and used as a medium for transferring recombinant genetic material into a host cell. The main types of vectors include plasmids, bacteriophages, viruses, cosmids, and artificial chromosomes. The vector itself is usually composed of a DNA sequence consisting of an insert (heterologous nucleic acid sequence, transgene) and a larger sequence that serves as the vector "backbone"; optionally, the vector backbone is taken from the pCDM4 plasmid.
[0065] The term "recombinant cell" used in the present invention refers to any cell type that is easy to be transformed, transfected, transduced, etc. with a nucleic acid construct or expression vector comprising the polynucleotide of the present invention, and it covers any parent cell progeny that is not identical to the parent cell due to the mutation that occurs during replication. In some embodiments, the "recombinant cell" can be any cell useful in the recombinant production of methyltransferase mutants, such as a prokaryotic cell or a eukaryotic cell. Wherein, the prokaryotic host cell can be any Gram-positive or Gram-negative bacteria. Gram-positive bacteria include but are not limited to: Bacillus, Clostridium, Enterococcus, Geobacillus, Lactobacillus, Lactococcus, Oceanic Bacillus, Staphylococcus, Streptococcus and Streptomyces. Gram-negative bacteria include but are not limited to Campylobacter, Escherichia coli, Flavobacterium, Fusobacterium, Helicobacter, Mud Bacillus, Neisseria, Pseudomonas, Salmonella and Ureaplasma. The eukaryotic host cell can be a mammal, insect, plant or fungal cell.
[0066] The term "mutant" as used in the present invention means a polypeptide having methyltransferase activity, comprising changes (i.e., substitutions, insertions and / or deletions) at one or more (e.g., several) positions. Substitution means replacing the amino acid occupying a certain position with a different amino acid; deletion means removing the amino acid occupying a certain position; and insertion means adding an amino acid adjacent to and immediately following the amino acid occupying a certain position.
[0067] In some embodiments, the methyltransferase mutant is substituted at position 43 and / or position 98 based on the amino acid sequence as shown in SEQ ID NO. 1. The mutant of the present invention has at least 20% of the activity of the methyltransferase parent enzyme, such as at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 100%.
[0068] The amino acid residues or mutants of the present invention are described using the accepted IUPAC single-letter or three-letter amino acid abbreviations. For amino acid substitutions, the following nomenclature is used: original amino acid, position, substituted amino acid. For example, mutant W98A represents that the 98th tryptophan is mutated to alanine based on the parent.
[0069] As used herein, the term "identity" refers to the degree of similarity between two or more biological sequences (such as DNA, RNA or polypeptide sequences).
[0070] (II) Reagents and materials
[0071] Primer Star MasterMix was purchased from Takara Corporation.
[0072] (III) Culture medium
[0073] LB medium: peptone 10g / L, yeast powder 5g / L, sodium chloride 10g / L. Add 20g / L agar to prepare LB solid medium.
[0074] Fermentation medium: glucose 35g / L, (NH4)2SO4 5g / L, KH2PO4 3g / L, MgSO4·7H2O 3g / L, NaCl1g / L, citric acid 1.5g / L, CaCl2·2H2O 0.015g / L, FeSO4·7H2O 0.1125g / L, vitamin B10.075g / L, tryptone 4g / L, yeast powder 2g / L, Al2(SO4)3·18H2O 2.0g / L, CoSO4·7H2O 0.75g / L, CuSO4·5H2O2.5g / L, H3BO3 0.5g / L, MnSO4·H2O 24g / L, Na2MoO4·2H2O 3.0g / L, NiSO4·6H2O2.5g / L, ZnSO4·7H2O 15g / L.
[0075] (IV) Detection methods
[0076] HPLC detection of vanillin:
[0077] The detection was performed using a C18 column (250×4.6 mm, 5 μm, Waters, USA) at 40°C using a Waters ArcHPLC system and a detector 2480. The mobile phase A was set to pure water containing 1‰ (v / v) trifluoroacetic acid, and the mobile phase B was set to acetonitrile containing 1‰ (v / v) trifluoroacetic acid. The flow rate was 1 mL min -1 , detection wavelength was 250nm, 10% B was the initial concentration, and the elution gradient was 0-10min 40% B; 10-20min, linear elution to 60% B, 20-23min 60% B; 23-25min, linear elution to 10% B; 25-27min 10% B.
[0078] (V) Genetic Engineering Operations
[0079] E. coli electroporation method:
[0080] Preparation of electroporation competent cells: Streak E. coli cells on LB plates, culture at 37°C overnight, pick a single colony and inoculate it into 5 mL of LB liquid medium, culture at 37°C 220 rpm with shaking for 10-12 h, transfer to 50 mL of LB liquid medium, and culture at 37°C 220 rpm with shaking for about 1.5-2 h until OD reaches 600 The value is between 0.6 and 0.8;
[0081] Collect the bacterial solution and precool it on ice for 5 minutes, centrifuge it at 4500×g for 5 minutes to collect the cells, add 25mL of precooled 10% glycerol to resuspend the cells, centrifuge it at 4500×g for 5 minutes to collect the cells, repeat the above steps once, add 5mL of 10% glycerol to resuspend the cells, take 100μL of the resuspended solution and dispense it into 1.5mL centrifuge tubes, and put it on ice for use;
[0082] Electroporation: Melt the vector on ice, add no less than 600 ng of the vector to the resuspension, pipette and mix, and let stand on ice for 10-15 min;
[0083] Turn on the electroporator and set the voltage to 1800V. Pipette the heavy suspension mixed with the vector into the electroporation cup. After electroporation, quickly add 1mL of LB liquid culture medium and pipette to mix. Transfer the electroporated bacterial solution into a 1.5mL centrifuge tube and incubate at 30℃ for 1.5-2h. Centrifuge the incubated bacterial solution at 6000×g for 2min, discard 900μl of the supernatant, pipette to mix the remaining liquid and apply it to the LB plate with the corresponding resistance, and culture at 37℃ overnight.
[0084] Gibson assembly method: The reaction system is as follows: add 50ng of DNA fragment, 100ng of vector, 5μl of Gibson mix, and add sterile ultrapure water to 10μl of the system. The reaction conditions are as follows: 50℃ for 60min, and put on ice immediately after the reaction. Take 10μl and transform it into E. coli competent JM109.
[0085] Example 1: Construction of molecular docking model of binary complex of methyltransferase LiOMT enzyme::cofactor
[0086] Based on the reported crystal structure of methyltransferase LiOMT::SAH (PDB number: 2HNK), the molecular docking model of the binary complex of methyltransferase LiOMT::cofactor SAM was first constructed. Using the homology modeling module in the software Discovery Studio2021, with 2HNK as the reference model, the SAM molecule was virtually docked into the methyltransferase LiOMT and a computer simulation prediction was performed. From the prediction results, the individuals with the highest binding energy were selected according to the binding of SAH in 2HNK to obtain the molecular docking model of the binary complex of methyltransferase LiOMT::cofactor SAM. The model schematic diagram is shown in Figure 3 On this basis, the molecular docking model of the ternary complex of methyltransferase LiOMT enzyme:: cofactor:: protocatechuic acid can be constructed. Example 2: For constructing a ternary complex molecular docking model of methyltransferase LiOMT enzyme:: cofactor:: protocatechuic acid:: Mg 2+ Screening of reference models for molecular docking models of quaternary complexes
[0087] According to the reported crystal structure of methyltransferase LiOMT::SAH (PDB number: 2HNK), domain conservation was used as the core parameter for alignment, and multiple sequence alignment was performed in the Protein Data Bank (PDB) to obtain 500 sequences. From the 500 aligned sequences, individuals with sequence homology and structural similarity higher than 70% with methyltransferase LiOMT were selected, and at the same time, they had a quaternary complex crystal structure of enzyme::cofactor::benzene ring-containing substrate::metal ion, and finally 12 reference individuals were obtained. On this basis, the RMSD values of the structural superposition alignment of the 12 reference samples and the methyltransferase LiOMT were calculated respectively, and finally the individual 3CBG with the lowest RMSD value was selected. Therefore, 3CBG was used as the reference model for the methyltransferase LiOMT enzyme::cofactor::protocatechuic acid::Mg 2+ Construction of a quaternary complex molecular docking model.
[0088] Example 3: Construction of molecular docking model of ternary complex of methyltransferase LiOMT enzyme::cofactor::protocatechuic acid
[0089] According to the reference model 3CBG selected in Example 2, based on the binary complex molecular docking model of methyltransferase LiOMT::cofactor SAM constructed in Example 1, the homology modeling module in the software Discovery Studio 2021 was used, and 3CBG was used as the reference model. The protocatechuic acid molecule was virtually docked into the binary complex molecular docking model of methyltransferase LiOMT::cofactor SAM constructed in Example 1 and computer simulation prediction was performed. From the prediction results, the individual with the highest binding energy was selected according to the binding situation of the benzene ring-containing substrate in 3CBG to obtain the ternary complex molecular docking model of methyltransferase LiOMT::cofactor SAM::protocatechuic acid. The model schematic diagram is shown in Figure 4 On this basis, methyltransferase LiOMT enzyme:: cofactor:: protocatechuic acid:: Mg 2+ Construction of a quaternary complex molecular docking model.
[0090] Example 4: Methyltransferase LiOMT enzyme::cofactor::protocatechuic acid::Mg 2+ Construction of molecular docking model of quaternary complex
[0091] According to the reference model 3CBG selected in Example 2, based on the molecular docking model of the ternary complex of the methyltransferase LiOMT::cofactor SAM::protocatechuic acid constructed in Example 3, the homology modeling module in the software Discovery Studio 2021 was used, and 3CBG was used as the reference model to virtually dock the protocatechuic acid molecule into the ternary complex molecular docking model of the methyltransferase LiOMT::cofactor SAM::protocatechuic acid constructed in Example 3 and perform computer simulation prediction. From the prediction results, the individual with the highest binding energy was selected according to the binding situation of the benzene ring-containing substrate in 3CBG to obtain the methyltransferase LiOMT::cofactor SAM::protocatechuic acid::Mg 2+ The molecular docking model of the quaternary complex is shown in Figure 5 On this basis, the mutation sites of methyltransferase LiOMT can be screened.
[0092] Example 5: Preparation of alanine scanning mutants of methyltransferase LiOMT
[0093] According to the methyltransferase LiOMT::cofactor SAM::protocatechuic acid::Mg constructed in Example 4 2+ Molecular docking model of the quaternary complex with cofactor SAM::protocatechuic acid::Mg 2+ The center of the binding site of the methyltransferase LiOMT 32 amino acid residues were selected as spherecombinatorial active-site saturation test (CAST) sites. The selected 32 amino acid sites were mutated to alanine (Ala), primers for introducing alanine (Ala) mutations were designed and synthesized, site-directed mutagenesis was performed on the gene sequence of methyltransferase LiOMT (nucleotide sequence as shown in SEQ ID NO.2), and sequencing was performed to confirm whether the coding gene of the methyltransferase LiOMT mutant was correct.
[0094] Construction of plasmid pCDM4-NiCAR-LiOMT: The recombinant plasmid pCDM4-NiCAR-LiOMT carrying genes NiCAR and LiOMT was constructed by referring to the construction method of plasmid pCDM4-OR4 in the patent application with publication number CN116751730A, wherein the promoter PT7 on the plasmid pCDM4 was replaced with an inducible promoter P that can also be regulated by IPTG for expression. trc (The nucleotide sequence is shown in SEQ ID NO.10); the nucleotide sequences of genes NiCAR and LiOMT are shown in SEQ ID NO.9 and SEQ ID NO.2, respectively; there is an RBS sequence (tttgtttaactttaagaaggaga, as shown in SEQ ID NO.11) between genes NiCAR and LiOMT.
[0095] PCR amplification of site-directed mutant encoding gene: PCR technology was used, with the expression vector pCDM4-NiCAR-LiOMT carrying the gene encoding wild-type methyltransferase LiOMT as the template). PCR amplification was performed with the primer pairs designed for single-point mutations, respectively, using Primer Star MasterMix high-fidelity pfu enzyme, and the conditions were pre-denaturation at 95°C, 5min; 28 cycles of amplification at 95°C, 10s, 55°C, 10s, 72°C, 1min; extension at 72°C, 5min, and the PCR product was purified, and the PCR product was self-ligated by the Gibson assembly method to obtain a recombinant vector with a single-point mutation.
[0096] Table 1 Primer sequences
[0097]
[0098]
[0099]
[0100]
[0101] Example 6: Vanillin fermentation of alanine scanning mutant of methyltransferase LiOMT
[0102] The recombinant vector with a single point mutation of the shoelace methyltransferase LiOMT constructed in Example 5 and the expression vector pCDM4-NiCAR-LiOMT carrying the gene encoding the wild-type methyltransferase LiOMT were transformed into the strain K12R by electroporation, respectively, to obtain recombinant strains K12R-N42A to K12R-W85A carrying the methyltransferase LiOMT mutant gene constructed in Example 5 and the recombinant strain K12R-WT carrying the wild-type methyltransferase LiOMT gene, respectively.
[0103] The recombinant strain K12R-WT and the recombinant strains K12R-N42A to K12R-W85A were cultured on LB plates at 37°C overnight until single colonies grew; single colonies were picked up in liquid LB medium and cultured at 37°C and 220rpm for 10-12h as seed liquid; the seed liquid was transferred to a 250mL shake flask with a fermentation medium volume of 25mL at a 2% inoculation amount, and cultured at 37°C and 220rpm for 3.5-4h until OD 600 =0.8~1.0, add 0.5mM IPTG to start induction, culture at 30℃, 220rpm for 24h and then take a sample; add an equal volume of acetonitrile to the fermentation broth and shake and mix, centrifuge at 12000×g for 5min to collect the supernatant. Filter the supernatant with a 0.22μm filter membrane into a liquid phase vial for HPLC detection. The results showed that 107.1mg / L vanillin was detected in the fermentation broth of the recombinant strain K12R-W98A carrying the methyltransferase LiOMT mutant gene constructed in Example 5, and 93.3mg / L vanillin was detected in the recombinant strain K12R-WT carrying the wild-type methyltransferase LiOMT gene. The expression of the methyltransferase LiOMT mutant W98A can increase the accumulation of vanillin by about 12.8%.
[0104] Example 7: Saturation mutation of methyltransferase LiOMT
[0105] Based on the mutant W98A obtained in Example 6, the tryptophan (Trp) at the 98th position of the methyltransferase LiOMT was subjected to saturated amino acid mutation, and was mutated to glycine (Gly), valine (Val), leucine (Leu), isoleucine (Ile), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), cysteine (Cys), tyrosine (Tyr), asparagine (Asn), glutamine (Gln), aspartic acid (Asp), glutamic acid (Gln), lysine (Lys), arginine (Arg), histidine (His). Primers for introducing saturated mutations were designed and synthesized respectively, and the gene sequence of the methyltransferase LiOMT was subjected to site-directed mutation, and sequencing was performed to confirm whether the coding gene of the methyltransferase LiOMT mutant was correct.
[0106] PCR amplification of site-directed mutant encoding gene: PCR technology was used, with the expression vector pCDM4-NiCAR-LiOMT plasmid carrying the wild-type methyltransferase LiOMT gene as the template. PCR amplification was performed with the primer pairs designed for single-point mutations, using Primer Star MasterMix high-fidelity pfu enzyme, under the conditions of pre-denaturation at 95°C for 5 min; 28 cycles of amplification at 95°C for 10 s, 55°C for 10 s, and 72°C for 1 min; extension at 72°C for 5 min, and the PCR product was purified, and the PCR product was self-ligated by the Gibson assembly method to obtain a recombinant vector with a single point mutation.
[0107] Table 2 Primer sequences for amino acid saturation mutation at position 98
[0108] Primer Sequence 5’-3’ R33 TTCTTCGCTCACATCGCAGCACAGAATTTTGC F33 GCTGCGATGTGAGCGAAGAAGGGACCAACGTGGCGCGCAAATATTGG F34 GCTGCGATGTGAGCGAAGAAGTGACCAACGTGGCGCGCAAATATTGG F35 GCTGCGATGTGAGCGAAGAACTGACCAACGTGGCGCGCAAATATTGG F36 GCTGCGATGTGAGCGAAGAAATGACCAACGTGGCGCGCAAATATTGG F37 GCTGCGATGTGAGCGAAGAAATGACCAACGTGGCGCGCAAATATTGG F38 GCTGCGATGTGAGCGAAGAATTCACCAACGTGGCGCGCAAATATTGG F39 GCTGCGATGTGAGCGAAGAACCGACCAACGTGGCGCGCAAATATTGG F40 GCTGCGATGTGAGCGAAGAATCGACCAACGTGGCGCGCAAATATTGG F41 GCTGCGATGTGAGCGAAGAAACGACCAACGTGGCGCGCAAATATTGG F42 GCTGCGATGTGAGCGAAGAATGCACCAACGTGGCGCGCAAATATTGG F43 GCTGCGATGTGAGCGAAGAATACACCAACGTGGCGCGCAAATATTGG F44 GCTGCGATGTGAGCGAAGAAAACACCAACGTGGCGCGCAAATATTGG F45 GCTGCGATGTGAGCGAAGAACAGACCAACGTGGCGCGCAAATATTGG F46 GCTGCGATGTGAGCGAAGAAGACACCAACGTGGCGCGCAAATATTGG F47 GCTGCGATGTGAGCGAAGAAGAGACCAACGTGGCGCGCAAATATTGG F48 GCTGCGATGTGAGCGAAGAAAAGACCAACGTGGCGCGCAAATATTGG F49 GCTGCGATGTGAGCGAAGAACGGACCAACGTGGCGCGCAAATATTGG F50 GCTGCGATGTGAGCGAAGAACACACCAACGTGGCGCGCAAATATTGG
[0109] The recombinant vector of the single-point mutation of the methyltransferase LiOMT constructed above was transformed into the strain K12R by electroporation, and the recombinant strains K12R-W98A to K12R-W98H carrying the mutant gene of the methyltransferase LiOMT constructed above were obtained.
[0110] The recombinant strains K12R-W98A to K12R-W98H were cultured on LB plates at 37°C overnight until a single colony grew; a single colony was picked up in a liquid LB medium and cultured at 37°C and 220rpm for 10-12h as a seed solution; the seed solution was transferred to a 250mL shake flask containing 25mL of fermentation medium at a 2% inoculation rate, and cultured at 37°C and 220rpm for 3.5-4h until OD 600=0.8~1.0, add 0.5mM IPTG to start induction, culture at 30℃, 220rpm for 24h and then take a sample; add an equal volume of acetonitrile to the fermentation broth and shake and mix, centrifuge at 12000×g for 5min to collect the supernatant; filter the supernatant with a 0.22μm filter membrane into a liquid phase vial for HPLC detection. The recombinant strain K12R-WT was used as a control and fermented in the same way as above. The results showed that 117.7mg / L vanillin was detected in the fermentation broth of the recombinant strain K12R-W98K. Compared with the vanillin production of the recombinant strain K12R-WT (90.2mg / L), the methyltransferase LiOMT mutant W98K can increase the vanillin accumulation of the strain by 23.3%.
[0111] Example 8: Iterative saturation mutagenesis of methyltransferase LiOMT
[0112] On the basis of the methyltransferase LiOMT mutant W98K constructed in Example 7, the 43rd position methionine (Met) which also improves the yield of vanillin in alanine scanning is subjected to amino acid saturation mutation. They are mutated to glycine (Gly), valine (Val), leucine (Leu), isoleucine (Ile), tryptophan (Trp), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), cysteine (Cys), tyrosine (Tyr), asparagine (Asn), glutamine (Gln), aspartic acid (Asp), glutamic acid (Gln), lysine (Lys), arginine (Arg), histidine (His). Primers for introducing saturation mutations are designed and synthesized respectively, and site-directed mutations are carried out on the gene sequence of methyltransferase LiOMT, and sequencing is performed to confirm whether the coding gene of methyltransferase LiOMT mutant is correct.
[0113] PCR amplification of site-directed mutant encoding gene: PCR technology was used, with the expression vector pCDM4-W98K plasmid carrying the wild-type methyltransferase LiOMT gene as the template. PCR amplification was performed with the primer pairs designed for single-point mutations, respectively, using Primer Star MasterMix high-fidelity pfu enzyme, and the conditions were pre-denaturation at 95°C, 5min; 28 cycles of amplification at 95°C, 10s, 55°C, 10s, 72°C, 1min; extension at 72°C, 5min, and the PCR product was purified, and the PCR product was self-ligated by the Gibson assembly method to obtain a recombinant vector with a single point mutation.
[0114] Table 3 Primer sequences for amino acid saturation mutation at position 43
[0115]
[0116]
[0117] The recombinant vector of iterative mutation of methyltransferase LiOMT constructed above was transformed into strain K12R by electroporation to obtain recombinant strains K12R-W98K / M43A~K12R-W98K / M43H carrying the mutant gene of methyltransferase LiOMT constructed above. The recombinant strains K12R-W98K / M43A~K12R-W98K / M43H were cultured on LB plates at 37°C overnight until a single colony grew; a single colony was picked in liquid LB culture medium and cultured at 37°C and 220rpm for 10~12h as seed liquid; the seed liquid was transferred to a 250mL shake flask with a fermentation medium volume of 25mL at a 2% inoculation amount, and cultured at 37°C and 220rpm for 3.5~4h until OD 600 =0.8~1.0, add 0.5mM IPTG to start induction, culture at 30℃, 220rpm for 24h and then take a sample; add an equal volume of acetonitrile to the fermentation broth and shake and mix, centrifuge at 12000×g for 5min to collect the supernatant; filter the supernatant with a 0.22μm filter membrane into a liquid phase vial for HPLC detection. The recombinant strain K12R-WT was used as a control and fermented in the same way as above. The results showed that 127.7mg / L vanillin was detected in the fermentation broth of the recombinant strain K12R-W98K / M43Y. Compared with the yield of the recombinant strain K12R-WT (93.3mg / L), the expression of the methyltransferase LiOMT mutant W98K / M43Y can increase the accumulation of vanillin by about 26.4%.
[0118] Example 9: Strain expressing methyltransferase LiOMT-W98K / M43Y mutant synthesizes vanillin in a fermenter
[0119] The recombinant strain carrying the methyltransferase LiOMT mutant W98K / M43Y obtained in Example 8 was fermented in a 5L fermenter to produce vanillin. The specific steps are:
[0120] The recombinant strain K12R-M43Y was cultured on an LB plate at 37°C overnight until a single colony grew; a single colony was picked and placed in a liquid LB medium, and cultured at 37°C and 220rpm for 10-12h as a seed solution; the seed solution was transferred to a 250mL shake flask with a volume of 25mL fermentation medium at a 2% inoculation amount as a first-level seed solution, and cultured at 37°C and 220rpm for 10-12h; and then transferred to a 250mL shake flask with a volume of 50mL LB at a 2% inoculation amount, and cultured at 37°C and 220rpm for 8-10 hours as a second-level seed solution. The second-level seed liquid was transferred to a 5L fermentation tank with 2.5L fermentation medium at a 10% inoculation amount, cultured at 37°C until the dissolved oxygen rebounded, then cooled to 30°C, added with a final concentration of 0.5mM IPTG for induction and began to feed (the feeding solution was 600g / L glucose solution), the dissolved oxygen was controlled at 40% during the fermentation process, the feeding flow rate was 20ml / h, and the pH was controlled at 6.5±0.05 by automatically adding 50% ammonia water. The fermentation broth at the end of fermentation was added with an equal volume of acetonitrile and shaken and mixed, and the supernatant was collected by centrifugation at 12000×g for 5min; the supernatant was filtered into a liquid phase vial with a 0.22μm filter membrane and tested by HPLC.
[0121] The results showed that 683.1 mg / L vanillin was detected in the recombinant strain K12R-W98K / M43Y carrying the methyltransferase LiOMT mutant W98K / M43Y constructed in Example 8 after 60 h of fermentation, reaching the highest level of de novo vanillin synthesis reported so far.
[0122] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.
Claims
1. A methyltransferase mutant with improved enzyme activity, characterized in that: Compared to a parent derived from Leptospira interrogans, having mutations of (a) and / or (b): (a) the tryptophan at position 98 is mutated to alanine, or leucine, or isoleucine, or methionine, or serine, or lysine; (b) Methionine at position 43 was mutated to cysteine or tyrosine.
2. The methyltransferase mutant according to claim 1, characterized in that The amino acid sequence of the parent is shown in SEQ ID NO.
1.
3. A gene encoding the mutant according to claim 1 or 2.
4. An expression vector carrying the gene according to claim 3.
5. The expression vector according to claim 4, characterized in that The vector includes but is not limited to pCDM4 plasmid.
6. A recombinant microbial cell expressing the methyltransferase mutant according to claim 1, or containing the gene according to claim 3.
7. A recombinant Escherichia coli, characterized in that The methyltransferase mutant according to claim 1 or 2 is expressed.
8. The recombinant Escherichia coli according to claim 7, characterized in that The Escherichia coli is able to synthesize vanillin using glucose.
9. The recombinant Escherichia coli according to claim 7 or 8, characterized in that The mutant according to claim 1 or 2 is expressed using pCDM4 as a vector.
10. A method for preparing vanillin, characterized in that: The recombinant Escherichia coli according to any one of claims 7 to 9 is cultured in a medium containing glucose.
11. The method according to claim 10, characterized in that The culture is first cultured at 35-37°C for a period of time, then IPTG is added for induction, and the culture is continued at 28-30°C.
12. The method according to claim 10, characterized in that Feeding is also performed during the culture process.
13. The method according to claim 12, characterized in that The feed is to add glucose so that the glucose concentration in the fermentation liquid is less than 10 g / L.
14. Use of the mutant according to claim 1 or 2, or the recombinant microorganism according to claim 6, or the recombinant Escherichia coli according to any one of claims 7 to 9, or the method according to any one of claims 10 to 13 in the preparation of vanillin or a product containing vanillin.
Citation Information
Cited By
Recombinant engineering bacteria for in-situ oxidation to improve vanillin yield and construction method thereof
CN122898444A
